SCHEMBL5027255

SCHEMBL5027255

CCCC[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1NC(=O)CNC(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
GAA P10253 1/20 0.43
CCR2 P41597 4/20 0.42
CCR3 P51677 1/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP2D6 P10635 1/20 0.41
KCNH2 Q12809 1/20 0.41
CCR5 P51681 1/20 0.41
CPB1 P15086 2/20 0.41
KDM1A O60341 1/20 0.40
RCOR1 Q9UKL0 1/20 0.40
CYP3A4 P08684 1/20 0.40
MCHR1 Q99705 1/20 0.38
TPSAB1 Q15661 1/20 0.38
TPSD1 Q9BZJ3 1/20 0.38
TPSG1 Q9NRR2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5027250 1.00 ALDH1A1 (0.52) ALDH1A1GAACCR2CCR3TSHR
SCHEMBL5027258 1.00 ALDH1A1 (0.52) ALDH1A1GAACCR2CCR3TSHR
SCHEMBL5029150 0.89 ALDH1A1 (0.55) ALDH1A1GAACCR2CCR3TSHR
SCHEMBL5029161 0.89 ALDH1A1 (0.55) ALDH1A1GAACCR2CCR3TSHR
SCHEMBL5027168 0.79 ALDH1A1 (0.50) ALDH1A1GAACCR2CCR3TSHR
SCHEMBL5027262 0.79 CPB1 (0.34) ALDH1A1GAATSHRMAPK1CYP2D6
SCHEMBL5031884 0.76 CCR2 (0.62) CCR2CYP2D6KCNH2CCR5
SCHEMBL5031887 0.76 CCR2 (0.62) CCR2CYP2D6KCNH2CCR5
SCHEMBL5031881 0.76 CCR2 (0.62) CCR2CYP2D6KCNH2CCR5
SCHEMBL5029448 0.75 CCR2 (0.71) CCR2CYP2D6KCNH2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 ALDH1A1 827/4885GAA 4005/4885CCR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.